Compare Amylx Pharmaceuticals Inc (AMLX) vs Fubotv Inc (FUBO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Fubotv Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Fubotv Inc trades at $9.16 (market cap $270.29M). The key difference: Amylx Pharmaceuticals Inc is far larger — about 7.3× Fubotv Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Fubotv Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | FUBO | |
|---|---|---|
Market Cap | $1.98B | $270.29M |
Sector | Health | Technology |
52-Week High | $18.70 | $54.72 |
52-Week Low | $7.64 | $8.09 |
Enterprise Value | $1.70B | $440.71M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
FUBO stock trades at $9.18, down 3.57% on the day, amid a bearish technical signal. The company shows improving fundamentals with revenue reaching $1.62B in 2024 and a projected net income margin of 7.61% for 2025, while valuation ratios like P/E of 2.39 and P/S of 0.18 appear attractive. Recent news highlights the appointment of Alisa Bowen as CEO, bringing media industry experience.
The outlook is mixed; analyst consensus is a Buy with a $16.25 price target, but risks include persistent negative cash flows, high debt levels, and competitive pressures in streaming. Investor sentiment is cautious pending execution of the new leadership's strategy and path to sustained profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →
